MET and non-small cell lung carcinoma: Additionally, in a phase II study using the same anti-MET therapeutic antibody (in combination with erlotinib) in patient with advance non-small cell lung cancer, MET expression, as accessed by immunohistochemistry, represented a robust predictor of OS and PFS [35].